Prevention of early graft occlusion after coronary bypass grafting by post-operative reduction of plasma fibrinogen by H.E.L.P. apheresis;Verhinderung von Frühverschlüssen nach koronarer Bypassoperation durch postoperative Reduktion des Plasmafibrinogens mittels H.E.L.P.-Apherese

Zeitschrift fur Kardiologie

Volumn 92, Issue SUPPL. 3, 2003, Pages 42-47

  Blessing, F ^a   Jaeger, B R ^a   Oberhoffer, M ^a   Reichart, B ^a   Seidel, D ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Coronary artery bypass grafting; Early graft occlusion; Fibrinogen (reduction); H.E.L.P. apheresis

Indexed keywords

FIBRINOGEN; HEPARIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE PHASE RESPONSE; ADULT; AGED; ANGIOCARDIOGRAPHY; APHERESIS; ARTICLE; BLEEDING; BLOOD RHEOLOGY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FIBRINOGEN BLOOD LEVEL; GRAFT OCCLUSION; GRAFT PATENCY; HEMOSTASIS; HEPARIN INDUCED EXTRACORPOREAL LOW DENSITY LIPOPROTEIN PRECIPITATION; HUMAN; MALE; PATHOPHYSIOLOGY; PATIENT MONITORING; PILOT STUDY; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; THROMBOGENESIS; TREATMENT OUTCOME;

ANTICOAGULANTS; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; EXTRACORPOREAL CIRCULATION; FIBRINOGEN; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HEPARIN; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PRECIPITATION; TREATMENT OUTCOME;

EID: 0346501906     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Akgün S, Ertel N, Mosenthal A, Oser W (1998) Postsurgical reduction of serum lipoproteins: interleukin-6 and the acute-phase response. J Lab Clin Med 131:103-108
2. Armstrong VW, Windisch M, Wieland H, Fuchs C, Rieger J, Köstering H, Nebendahl K, Scheler F, Seidel D (1983) Selective continous extracorporal elimination of low density lipoproteins with heparin at acid pH. Trans Am Soc Art Intern Organs 29:323-327
3. Benderly M (1996) Fibrinogen is a predictor of mortality in coronary heart disease patients atheriosclerosis thromb and vascular biology, Vol 16, No 3, pp 351-356
4. Cremer P, Nagel D, Seidel D, van de Loo JC, Kienast J (1996) Considerations about plasma fibrinogen concentration and the cardiovascular risk: combined evidence from the GRIPS and ECAT studies. Goettingen Risk, Incidence and Prevalence Study. European Concerted Action on Thrombosis and Disabilities [letter]. Am J Cardiol 78(3):380-381
5. FitzGibbon Gerald M et al (1996) Coronary bypass graft fate and patient outcome: angiographic follow-up of 5065 grafts related to survival and reoperation in 1388 patients during 25 years. JACC 28(3):616-626
6. Fatah K (1992) Fibrin gel network characteristics and coronary heart disease; relations to plasma fibrinogen concentrations, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Hemostasis 68:130-135
7. Fuster V, Badimon L, Badimon JJ, Chesebro JH (1992) The pathogenesis of coronary artery disease and the acute coronary syndromes. First of two parts. NEJM 326(4):224-250
8. Gurewich V, Lipinski B, Hyde E (1976) The effect of the fibrinogen concentration and the leucocyte count on intravascular fibrin deposition from soluble fibrin monomer complexes. Thromb Hemostasis 36:105
9. Kannel WB (1987) Fibrinogen and risk of cardiovascular disease. JAMA 258:1183-1186
10. Kleophans W, Leschke M, Tschöpe D, Martin J, Schauseil S, Strauber BE, Gries FA (1990) Akute Wirkungen der extrakorporalen LDL-Cholesterin-und Fibrinogen-Elimination auf Blutrheologie und Mikrozirkulation. Dtsch med Wschr 115:7-11
11. Koenig W, Ernst E (1992) The possible of hemorrheology and atherothrombogenesis. Atherosclerosis 94:93-107
12. Koenig W (1998) Plasma viscosity and the risk of coronary heart disease results from the MONICA-Augsburg cohort study. Atheroscler Thromb Vasc Biol 18:768-772
13. Kroon A (1996) Effect of apheresis of low-density lipoprotein (LDL) on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 125: 945-954
14. Lechner H, Walzl M, Walzl B (1993) The position of heparin-induced LDL precipitation (H.E.L.P.) in haemorheological research in cerebrovascular disease. Clin Hemorheol 13:637-639
15. Lechner H, Walzl M, Walzl B (1994) The impact of H.E.L.P. on haemorheology in peripheral arterial disease. Clin Hemiorheol 14:181-188
16. Lowe GDO (1997) Blood viscosity and the risk of cordiovascular events the Endinburgh Artery Study. Br J Haematol 96:168-173
17. Mellwig KP et al (1998) Improvement of coronary vasodilatation capacity through single LDL apheresis. Atherosklerosis 139:173-178
18. Moran S. V, Baeza R, Guarda E, Zalaquett R, Irarrazaval M, Marchant E, Deck C (2001) Predictors of radial artery patency for coronary bypass operations. Ann Thorac Surg 72:1552-1556
19. Paz MA, Lupon J, Bosch X, Pomar JL, Sanz G, and the GESIC Study Group (1993) Predictors of early saphenous vein aortocoronary bypass graft occlusion. Ann Thorac Surg 56:1101-1106
20. Schuff-Werner P (1996) Effects of LDL apheresis on the hemostatic system. Fibrinolysis 10 (Suppl 1):40
21. Schuff-Werner P, Schütz E, Reitemeyer F, Oppermann M, Eisenhauer T, Armstrong VW, Köstering H, Götze O, Seidel D (1990) Heparin induced extracorporal LDL-precipitation (H.E.L.P.): rheological, hemostaseological and immunological effects. In Gotto AM, Richter WO, Schwand P (ed) Treatment of severe hypercholesterolemia in the prevention of coronary heart disease. Karger, Basel 196-204
22. Schuff-Werner P, Schütz E, Seyde WC, Eisenhauer T, Jannings G, Armstrong VW, Seidel D (1989) Improved hemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin-induced extracorporeal LDL-precipitation (H.E.L.P.). Eur J Clin Invest 19:30-37
23. Seidel D H.E.L.P. Report 1994 (1994) 10 years of clinical experience MMV, pp 1-64
24. Seidel D, Armstrong VW (1991) The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-Apheresis in the secondary prevention of coronary heart disease. Evaluation of safety and cholesterol lowering effects during the first 12 months. Europ J Clin Invest 21375-21383
25. Shuaiber JH, Evans AN, Malek G, Geha A (2002) Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery. Europ J of Cardio-thoracic Surgery 22:387-396
26. Thompson S, Kienast J, Pyke S, Haverkate F, van de Loo J (1995) For the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic Factors and the Risk of Myocardial Infarction or sudden Death in Patients with Angina Pectoris. N Engl J of Med 332:635-641
27. Windler E, Ewers-Grabow U, Thiery J, Walli, Seidel D, Greten H (1994) The prognostic value of hypocholesterolemia in hospitalized patients. Clin Invest 72:939-943
28. Yarnell JWG (1991) Fibrinogen viscosity and white blood cell count are major risk factors of ischemic heart disease. Circulation 83:836-844